<p>根据其最近向美国证券交易委员会提交的 13F 文件，Orchard Capital Management LLC 在第二季度将其在 Intellia Therapeutics, Inc.（NASDAQ:NTLA - 免费报告）的持股减少了 57.3%。该公司在此期间出售了 106,288 股后，持有 79,208 股该公司的股票。Intellia Therapeutics 约占 Orchard Capital Management LLC 持股的 0.8%，使其成为该公司第 29 大持仓。截至其最近的 SEC 文件，Orchard Capital Management LLC 持有的 Intellia Therapeutics 的股份价值为 743,000 美元，约占 0.08%。</p>
<ul>
<li>高盛在其看涨的标准普尔 500 展望中重点关注这 3 只股票</li>
</ul>
<p>其他一些机构投资者也调整了他们对 NTLA 的持股。先锋集团（Vanguard Group Inc.）在第一季度将其在 Intellia Therapeutics 的持股增加了 5.5%。先锋集团目前持有 10,752,031 股该公司的股票，价值 76,447,000 美元，此前在此期间又增持了 561,978 股。Geode Capital Management LLC 在第二季度将其在 Intellia Therapeutics 的持股增加了 5.1%。Geode Capital Management LLC 目前持有 2,606,222 股该公司的股票，价值 24,449,000 美元，此前在上一季度又购买了 126,049 股。摩根大通（JPMorgan Chase &amp; Co.）在第二季度将其在 Intellia Therapeutics 的持股增加了 73.0%。摩根大通目前持有 940,483 股该公司的股票，价值 8,822,000 美元，此前在上一季度又增持了 396,858 股。Vestmark Advisory Solutions Inc.在第二季度将其在 Intellia Therapeutics 的持仓增加了 104.7%。Vestmark Advisory Solutions Inc.目前持有 638,342 股该公司的股票，价值 5,988,000 美元，此前在此期间又购买了 326,460 股。最后，瑞银资产管理美洲有限公司（UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC）在第一季度将其在 Intellia Therapeutics 的持股增加了 8.0%。瑞银资产管理美洲有限公司目前持有 521,706 股该公司的股票，价值 3,709,000 美元，此前在上一季度又增持了 38,521 股。机构投资者持有该公司 88.77% 的股票。</p>
<p>获取 <strong>Intellia Therapeutics</strong> 的提醒：</p>
<h2>Intellia Therapeutics 股票下跌 0.4%</h2>
<p>NTLA 周五开盘价为 8.52 美元。该公司的市值为 9.8687 亿美元，市盈率为-2.00，贝塔系数为 2.44。该公司的 50 日简单移动平均为 16.26 美元，200 日简单移动平均为 12.52 美元。Intellia Therapeutics, Inc.的 52 周最低价为 5.90 美元，52 周最高价为 28.25 美元。</p>
<ul>
<li>分析师认为这些股票的价值可能会翻倍</li>
</ul>
<p>Intellia Therapeutics（NASDAQ:NTLA - 获取免费报告）最近在 11 月 6 日（星期四）公布了其财报。该公司报告本季度每股收益（EPS）为-0.92 美元，超过分析师一致预期的-1.02 美元，超出 0.10 美元。Intellia Therapeutics 的股本回报率为-57.01%，净利润率为-774.94%。该公司本季度的收入为 1378 万美元，而分析师预期为 1412 万美元。在去年同期，该公司每股收益为-1.34 美元。与去年同期相比，Intellia Therapeutics 本季度的收入增长了 51.6%。平均而言，股票研究分析师预计 Intellia Therapeutics, Inc.在当前财政年度将发布-5.07 的每股收益。</p>
<h2>分析师评级变动</h2>
<p>一些研究分析师最近对 NTLA 股票发表了评论。HC Wainwright 在 11 月 10 日的研究报告中将 Intellia Therapeutics 的目标价从 18.00 美元下调至 15.00 美元，并给予该公司 “买入” 评级。Chardan Capital 在 11 月 7 日的报告中将 Intellia Therapeutics 的目标价从 48.00 美元下调至 26.00 美元，并给予该公司 “买入” 评级。Truist Financial 在 11 月 10 日的研究报告中重申了 “买入” 评级，并将 Intellia Therapeutics 的目标价设定为 14.00 美元（之前为 25.00 美元）。花旗集团在 10 月 28 日的报告中重申了 Intellia Therapeutics 的 “市场表现优于大盘” 评级。最后，Evercore ISI 在 11 月 11 日的研究报告中将 Intellia Therapeutics 的目标价设定为 8.00 美元，并给予该公司 “持平” 评级。共有 11 位研究分析师对该股票给予 “买入” 评级，10 位给予 “持有” 评级，3 位给予 “卖出” 评级。根据 MarketBeat 的数据，Intellia Therapeutics 的共识评级为 “持有”，共识目标价为 18.43 美元。</p>
<ul>
<li>2 只基因编辑股票在 2025 年有强劲反弹的潜力</li>
</ul>
<p><strong>查看我们关于 NTLA 的最新报告</strong></p>
<h2>Intellia Therapeutics 的内部交易</h2>
<p>在其他 Intellia Therapeutics 的新闻中，首席会计官 Michael P. Dube 在 10 月 1 日（星期三）出售了 1,871 股该公司的股票。该股票的平均售价为 17.38 美元，总交易额为 32,517.98 美元。出售完成后，首席会计官直接持有该公司 55,266 股股票，价值约为 960,523.08 美元。这代表其持股减少了 3.27%。该交易已在向证券交易委员会的文件中披露，相关文件可通过此链接获取。内部人士持有该公司 3.10% 的股票。</p>
<h2>Intellia Therapeutics 简介</h2>
<p>（免费报告）</p>
<p>Intellia Therapeutics, Inc.是一家基因编辑公司，专注于治愈性治疗的开发。该公司的体内项目包括 NTLA-2001，目前正在进行治疗转甲状腺素蛋白淀粉样变的 1 期临床试验；NTLA-2002 用于治疗遗传性血管性水肿；以及 NTLA-3001 用于与肺病相关的α-1 抗胰蛋白酶缺乏症。</p>
<h2>特色故事</h2>
<ul>
<li>我们更看好的五只股票，而不是 Intellia Therapeutics</li>
<li>三只防御类股票将受益于军事支出的增加</li>
<li>Semtech 的数据中心芯片如何推动 AI 热潮</li>
<li>ETF 筛选器：用途和逐步指南</li>
<li>Keysight Technologies 的激增：市场对这一 AI 投资的觉醒</li>
<li>市盈率计算：如何评估股票</li>
<li>美国运通是 K 型经济的信用股票吗？</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlRMQQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlRMQQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Intellia Therapeutics 吗？</h2>
<p>在考虑 Intellia Therapeutics 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前立即购买……而 Intellia Therapeutics 并不在名单上。</p>
<p>虽然 Intellia Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Intellia治疗

<p>Orchard Capital Management LLC 在第二季度减少了对 Intellia Therapeutics 的持股，减持幅度为 57.3%，出售了 106,288 股。Intellia 的股票现在是其第 29 大持仓，占其持有资产的 0.8%。其他机构投资者也调整了他们在 NTLA 的持仓。Intellia 的股票开盘价为 8.52 美元，市值为 9.8687 亿美元。分析师的评级各不相同，普遍目标价为 18.43 美元。Intellia 第三季度的收入同比增长 51.6%，每股收益超出预期</p>

<p>Orchard Capital Management LLC cut its holdings in Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 57.3% in the 2nd quarter, according to its most recent 13F filing with the SEC. The firm owned 79,208 shares of the company's stock after selling 106,288 shares during the period. Intellia Therapeutics comprises approximately 0.8% of Orchard Capital Management LLC's holdings, making the stock its 29th biggest position. Orchard Capital Management LLC owned 0.08% of Intellia Therapeutics worth $743,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>根据其最近向美国证券交易委员会提交的 13F 文件，Orchard Capital Management LLC 在第二季度将其在 Intellia Therapeutics, Inc.（NASDAQ:NTLA - 免费报告）的持股减少了 57.3%。该公司在此期间出售了 106,288 股后，持有 79,208 股该公司的股票。Intellia Therapeutics 约占 Orchard Capital Management LLC 持股的 0.8%，使其成为该公司第 29 大持仓。截至其最近的 SEC 文件，Orchard Capital Management LLC 持有的 Intellia Therapeutics 的股份价值为 743,000 美元，约占 0.08%。</p>
</div><ul>
<li>Goldman Spotlights These 3 Stocks in Its Bullish S&amp;P 500 Outlook</li>
</ul>
<div class="lb-trans"><ul>
<li>高盛在其看涨的标准普尔 500 展望中重点关注这 3 只股票</li>
</ul>
</div><p>A number of other institutional investors have also modified their holdings of NTLA. Vanguard Group Inc. raised its stake in Intellia Therapeutics by 5.5% during the first quarter. Vanguard Group Inc. now owns 10,752,031 shares of the company's stock worth $76,447,000 after acquiring an additional 561,978 shares during the period. Geode Capital Management LLC grew its holdings in shares of Intellia Therapeutics by 5.1% during the second quarter. Geode Capital Management LLC now owns 2,606,222 shares of the company's stock valued at $24,449,000 after purchasing an additional 126,049 shares during the last quarter. JPMorgan Chase &amp; Co. grew its holdings in shares of Intellia Therapeutics by 73.0% during the second quarter. JPMorgan Chase &amp; Co. now owns 940,483 shares of the company's stock valued at $8,822,000 after purchasing an additional 396,858 shares during the last quarter. Vestmark Advisory Solutions Inc. raised its position in shares of Intellia Therapeutics by 104.7% during the 2nd quarter. Vestmark Advisory Solutions Inc. now owns 638,342 shares of the company's stock worth $5,988,000 after purchasing an additional 326,460 shares during the period. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Intellia Therapeutics by 8.0% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 521,706 shares of the company's stock worth $3,709,000 after purchasing an additional 38,521 shares during the last quarter. Institutional investors own 88.77% of the company's stock.</p>
<div class="lb-trans"><p>其他一些机构投资者也调整了他们对 NTLA 的持股。先锋集团（Vanguard Group Inc.）在第一季度将其在 Intellia Therapeutics 的持股增加了 5.5%。先锋集团目前持有 10,752,031 股该公司的股票，价值 76,447,000 美元，此前在此期间又增持了 561,978 股。Geode Capital Management LLC 在第二季度将其在 Intellia Therapeutics 的持股增加了 5.1%。Geode Capital Management LLC 目前持有 2,606,222 股该公司的股票，价值 24,449,000 美元，此前在上一季度又购买了 126,049 股。摩根大通（JPMorgan Chase &amp; Co.）在第二季度将其在 Intellia Therapeutics 的持股增加了 73.0%。摩根大通目前持有 940,483 股该公司的股票，价值 8,822,000 美元，此前在上一季度又增持了 396,858 股。Vestmark Advisory Solutions Inc.在第二季度将其在 Intellia Therapeutics 的持仓增加了 104.7%。Vestmark Advisory Solutions Inc.目前持有 638,342 股该公司的股票，价值 5,988,000 美元，此前在此期间又购买了 326,460 股。最后，瑞银资产管理美洲有限公司（UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC）在第一季度将其在 Intellia Therapeutics 的持股增加了 8.0%。瑞银资产管理美洲有限公司目前持有 521,706 股该公司的股票，价值 3,709,000 美元，此前在上一季度又增持了 38,521 股。机构投资者持有该公司 88.77% 的股票。</p>
</div><p>Get <strong>Intellia Therapeutics</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Intellia Therapeutics</strong> 的提醒：</p>
</div><h2>Intellia Therapeutics Stock Down 0.4%</h2>
<div class="lb-trans"><h2>Intellia Therapeutics 股票下跌 0.4%</h2>
</div><p>NTLA opened at $8.52 on Friday. The firm has a market cap of $986.87 million, a PE ratio of -2.00 and a beta of 2.44. The business has a fifty day simple moving average of $16.26 and a 200-day simple moving average of $12.52. Intellia Therapeutics, Inc. has a fifty-two week low of $5.90 and a fifty-two week high of $28.25.</p>
<div class="lb-trans"><p>NTLA 周五开盘价为 8.52 美元。该公司的市值为 9.8687 亿美元，市盈率为-2.00，贝塔系数为 2.44。该公司的 50 日简单移动平均为 16.26 美元，200 日简单移动平均为 12.52 美元。Intellia Therapeutics, Inc.的 52 周最低价为 5.90 美元，52 周最高价为 28.25 美元。</p>
</div><ul>
<li>Analysts Think These Stocks Could More Than Double in Value</li>
</ul>
<div class="lb-trans"><ul>
<li>分析师认为这些股票的价值可能会翻倍</li>
</ul>
</div><p>Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last announced its earnings results on Thursday, November 6th. The company reported ($0.92) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.02) by $0.10. Intellia Therapeutics had a negative return on equity of 57.01% and a negative net margin of 774.94%.The company had revenue of $13.78 million for the quarter, compared to analyst estimates of $14.12 million. During the same period in the previous year, the firm earned ($1.34) earnings per share. Intellia Therapeutics's revenue for the quarter was up 51.6% compared to the same quarter last year. On average, equities research analysts anticipate that Intellia Therapeutics, Inc. will post -5.07 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>Intellia Therapeutics（NASDAQ:NTLA - 获取免费报告）最近在 11 月 6 日（星期四）公布了其财报。该公司报告本季度每股收益（EPS）为-0.92 美元，超过分析师一致预期的-1.02 美元，超出 0.10 美元。Intellia Therapeutics 的股本回报率为-57.01%，净利润率为-774.94%。该公司本季度的收入为 1378 万美元，而分析师预期为 1412 万美元。在去年同期，该公司每股收益为-1.34 美元。与去年同期相比，Intellia Therapeutics 本季度的收入增长了 51.6%。平均而言，股票研究分析师预计 Intellia Therapeutics, Inc.在当前财政年度将发布-5.07 的每股收益。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析师评级变动</h2>
</div><p>A number of research analysts recently commented on NTLA shares. HC Wainwright lowered their price objective on Intellia Therapeutics from $18.00 to $15.00 and set a &#34;buy&#34; rating for the company in a research note on Monday, November 10th. Chardan Capital reduced their price target on shares of Intellia Therapeutics from $48.00 to $26.00 and set a &#34;buy&#34; rating for the company in a report on Friday, November 7th. Truist Financial restated a &#34;buy&#34; rating and set a $14.00 price target (down previously from $25.00) on shares of Intellia Therapeutics in a research report on Monday, November 10th. Citigroup reaffirmed a &#34;market outperform&#34; rating on shares of Intellia Therapeutics in a report on Tuesday, October 28th. Finally, Evercore ISI set a $8.00 target price on shares of Intellia Therapeutics and gave the company an &#34;in-line&#34; rating in a research note on Tuesday, November 11th. Eleven research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and three have issued a Sell rating to the company's stock. Based on data from MarketBeat, Intellia Therapeutics has a consensus rating of &#34;Hold&#34; and a consensus target price of $18.43.</p>
<div class="lb-trans"><p>一些研究分析师最近对 NTLA 股票发表了评论。HC Wainwright 在 11 月 10 日的研究报告中将 Intellia Therapeutics 的目标价从 18.00 美元下调至 15.00 美元，并给予该公司 “买入” 评级。Chardan Capital 在 11 月 7 日的报告中将 Intellia Therapeutics 的目标价从 48.00 美元下调至 26.00 美元，并给予该公司 “买入” 评级。Truist Financial 在 11 月 10 日的研究报告中重申了 “买入” 评级，并将 Intellia Therapeutics 的目标价设定为 14.00 美元（之前为 25.00 美元）。花旗集团在 10 月 28 日的报告中重申了 Intellia Therapeutics 的 “市场表现优于大盘” 评级。最后，Evercore ISI 在 11 月 11 日的研究报告中将 Intellia Therapeutics 的目标价设定为 8.00 美元，并给予该公司 “持平” 评级。共有 11 位研究分析师对该股票给予 “买入” 评级，10 位给予 “持有” 评级，3 位给予 “卖出” 评级。根据 MarketBeat 的数据，Intellia Therapeutics 的共识评级为 “持有”，共识目标价为 18.43 美元。</p>
</div><ul>
<li>2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025</li>
</ul>
<div class="lb-trans"><ul>
<li>2 只基因编辑股票在 2025 年有强劲反弹的潜力</li>
</ul>
</div><p><strong>View Our Latest Report on NTLA</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 NTLA 的最新报告</strong></p>
</div><h2>Insider Transactions at Intellia Therapeutics</h2>
<div class="lb-trans"><h2>Intellia Therapeutics 的内部交易</h2>
</div><p>In other Intellia Therapeutics news, CAO Michael P. Dube sold 1,871 shares of the company's stock in a transaction dated Wednesday, October 1st. The shares were sold at an average price of $17.38, for a total transaction of $32,517.98. Following the completion of the sale, the chief accounting officer directly owned 55,266 shares of the company's stock, valued at approximately $960,523.08. This represents a 3.27% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available through this hyperlink. Insiders own 3.10% of the company's stock.</p>
<div class="lb-trans"><p>在其他 Intellia Therapeutics 的新闻中，首席会计官 Michael P. Dube 在 10 月 1 日（星期三）出售了 1,871 股该公司的股票。该股票的平均售价为 17.38 美元，总交易额为 32,517.98 美元。出售完成后，首席会计官直接持有该公司 55,266 股股票，价值约为 960,523.08 美元。这代表其持股减少了 3.27%。该交易已在向证券交易委员会的文件中披露，相关文件可通过此链接获取。内部人士持有该公司 3.10% 的股票。</p>
</div><h2>Intellia Therapeutics Profile</h2>
<div class="lb-trans"><h2>Intellia Therapeutics 简介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.</p>
<div class="lb-trans"><p>Intellia Therapeutics, Inc.是一家基因编辑公司，专注于治愈性治疗的开发。该公司的体内项目包括 NTLA-2001，目前正在进行治疗转甲状腺素蛋白淀粉样变的 1 期临床试验；NTLA-2002 用于治疗遗传性血管性水肿；以及 NTLA-3001 用于与肺病相关的α-1 抗胰蛋白酶缺乏症。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>特色故事</h2>
</div><ul>
<li>Five stocks we like better than Intellia Therapeutics</li>
<li>3 Defense Stocks Set to Benefit From Increased Military Spending</li>
<li>How Semtech’s Data Center Chips Are Powering the AI Boom</li>
<li>ETF Screener: Uses and Step-by-Step Guide</li>
<li>Keysight Technologies' Surge: The Market Wakes Up to This AI Play</li>
<li>P/E Ratio Calculation: How to Assess Stocks</li>
<li>Is American Express the Credit Stock For a K-Shaped Economy?</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票，而不是 Intellia Therapeutics</li>
<li>三只防御类股票将受益于军事支出的增加</li>
<li>Semtech 的数据中心芯片如何推动 AI 热潮</li>
<li>ETF 筛选器：用途和逐步指南</li>
<li>Keysight Technologies 的激增：市场对这一 AI 投资的觉醒</li>
<li>市盈率计算：如何评估股票</li>
<li>美国运通是 K 型经济的信用股票吗？</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TlRMQQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=NTLA"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Intellia Therapeutics Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Intellia Therapeutics 吗？</h2>
</div><p>Before you consider Intellia Therapeutics, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Intellia Therapeutics 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Intellia Therapeutics wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，以便在更广泛的市场注意到之前立即购买……而 Intellia Therapeutics 并不在名单上。</p>
</div><p>While Intellia Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Intellia Therapeutics 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Orchard Capital Management LLC 出售了 Intellia 治疗公司的股票，股票代码为$NTLA